CAGRILINTIDE
Minimum order 2 vials or 2 pens — delivery in 2 weeks
It's not GLP-1 — it's amylin, the other satiety switch. Together with semaglutide it delivered −20.4% in 3,417 people.
Illustrations of the product — not photos of a specific batch.
There's another road to fullness beyond the familiar GLP-1 — and cagrilintide opens it. It's an amylin analog, a hormone your body already makes, which says “I'm full” in its own way.
While the other molecules talk to the stomach and the brain, amylin goes straight to the brainstem — to the nucleus that closes the meal. Two languages, one message, and together it comes through louder.
And the numbers show it beautifully clearly. On its own, in a phase 2 trial, it reached −10.8% and even outperformed liraglutide 2. Combined with semaglutide, in 3,417 people, the journey reached −20.4% in 68 weeks 1.
The one thing worth knowing before you start: the body needs a little time to get used to the new language, with some digestive discomfort at first — it usually passes as the dose progresses.
Research use only, with quality we check before it reaches you — because a good ingredient deserves proper handling from start to finish.
A second switch, not the same button again. Cagrilintide is an amylin analog — a hormone released alongside insulin that shuts down appetite via a different pathway than GLP-1.
Mechanism: GLP-1 works in the stomach and brain. Amylin goes to the brainstem, to the same nucleus that ends a meal. That's why it doesn't just add up with the others — it synergizes.
Numbers, not marketing. On its own: −10.8% in 26 weeks, ahead of liraglutide 2. Together with semaglutide, in 3,417 people: −20.4% in 68 weeks, vs −3.0% on placebo 1.
The straight story: 79.6% of the combination group had digestive side effects, vs 39.9% on placebo 1. Mostly transient — but factor them into the titration.
For research use, not for human consumption. Everything you buy here is quality-controlled — the handling after that is your job.
The switch no other molecule here touches. Everything else in the category plays with GLP-1, GIP and glucagon. Cagrilintide is an amylin analog — a pancreatic hormone the body releases together with insulin, which says “I'm full” via a different route.
On its own, and only in phase 2: −10.8% in 26 weeks. In the same trial it was compared head-to-head with liraglutide 3.0 mg, an approved weight-loss drug — and beat it: 10.8% vs 9.0% 2.
And combined with semaglutide, the number changes league. The combination (CagriSema) in a phase 3 trial with 3,417 people, 68 weeks: −20.4% vs −3.0% on placebo 1. A difference of 17.3 percentage points.
Why the synergy works: two different satiety systems, not the same one twice. GLP-1 works in the brain and the stomach; amylin goes to the brainstem, to the same nucleus that ends a meal. That's why cagrilintide is rarely sold on its own.
And the honesty, because it matters here: in the large trial, 79.6% of the combination group had gastrointestinal side effects vs 39.9% on placebo 1. They were mostly transient and mild to moderate — but they were there.
Vial: 5 mg vial, 10 mg vial · Pens: 1 × 5 mg pen, 1 × 10 mg pen.
We don't keep it in stock — it's ordered in: minimum 2 items (vials or pens) from the special-order products, with free shipping, and it arrives in about 2 weeks.
€3 shipping + €3 cash-on-delivery fee. For orders of 2 vials or pens or more, shipping and the cash-on-delivery fee are free. Delivery time depends on the courier.
Cash on delivery, paid to the courier when it arrives. For an electronic money transfer (PayPal, Revolut, Wise, crypto), email us for the details: ellinikapeptidia@gmail.com
Yes: you have a 14-day right of withdrawal from delivery, as long as the seal is intact. Return costs are yours, unless the product was faulty or wrong. Terms of Use
Want something you don't see here? Write to us — we reply.
Related products
from €112.80 to €128.80
Minimum order 2 vials or 2 pens — delivery in 2 weeks
GLP-1 and glucagon — no GIP. −14.0% in 48 weeks, and discontinuations due to side effects on par with placebo.
from €139.20 to €155.20
Minimum order 2 vials or 2 pens — delivery in 2 weeks
Dual GLP-1 and glucagon receptor agonist: in phase 2 (n=387) it produced up to −14.9% body weight at 46 weeks.
from €102.40 to €118.40
Minimum order 2 vials or 2 pens — delivery in 2 weeks
In a 48-week phase 2 RCT (263 adults with obesity), weekly eloralintide produced dose-dependent weight loss of up to −20% at the 9 mg dose, versus −0.4% with placebo.
from €44 to €176
Minimum order 2 vials or 2 pens — delivery in 2 weeks
−24.2% body weight in 48 weeks, and −82% liver fat. A triple GLP-1, GIP and glucagon agonist: it makes you eat less and burn more.
from €44 to €176
Minimum order 2 vials or 2 pens — delivery in 2 weeks
−20.9% body weight in 72 weeks, in a study of 2,539 people. A dual GLP-1 and GIP agonist: two switches instead of one — which is why the numbers are in a different league from monotherapy.
from €44 to €176
Minimum order 2 vials or 2 pens — delivery in 2 weeks
−14.9% body weight in 68 weeks — and the only one of the group proven to reduce heart attack and stroke, in 17,604 people.
€0
Fill in and send. A person replies, not an automated message.